Safety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study

Abstract Purpose To evaluate the efficacy and safety of dexamethasone implantation in the supraciliary (SC) space, a novel and potential effective implantation site, compared to intravitreal (IV) application. Methods This prospective study included 39 eyes of 38 patients with macular oedema (ME) who underwent SC and IV dexamethasone implantation (SC-DEX and IV-DEX). Patients were randomly assigned to treatment groups and followed for 3 months. Preoperative and postoperative assessments included maximum retinal thickness (MRT), change in central retinal thickness between consecutive visits (ΔCRT), intraocular pressure (IOP), and best corrected visual acuity (BCVA). Results Both SC-DEX and IV-DEX groups showed significant MRT reductions during at follow-up. In the SC group, MRT significantly decreased at 1st and 3rd months ( p  = 0.0002 for both), but not at 1st week ( p  = 0.2517). In the IV-DEX group, significant reductions in MRT were observed at all postoperative visits: 1st week ( p  = 0.0002), 1st month ( p  = 0.0004), and 3rd month ( p  = 0.0003). There were no significant differences in the change in ΔCRT between the SC-DEX and IV-DEX groups at any visit ( p  > 0.05). IOP did not show significant changes ( p  > 0.05). BCVA improved significantly in the SC group compared to the IV-DEX group during the first week ( p  = 0.014). No other perioperative or postoperative sight-threatening complications were noted in either group, including hypotony or endophthalmitis. Conclusion SC-DEX shows promise as an alternative for managing ME, offering similar effectiveness to IV-DEX with safe profile. Further studies are needed to confirm its long-term safety and efficacy.